Since the Supreme Court's unanimous mifepristone ruling in 2024, the coverage has been relentlessly framed as a sweeping pro-choice victory. It wasn't.

The Court dismissed the case. Full stop.

What the Ruling Actually Said

The justices did NOT rule that the FDA's approval of mifepristone was legally sound, scientifically correct, or beyond challenge. They ruled that the specific plaintiffs — anti-abortion medical groups including the Alliance for Hippocratic Medicine — lacked standing to bring the case.

No standing means the Court never reached the merits. The underlying legal questions about the FDA's 2016 and 2021 rule changes expanding mifepristone access remain untouched.

Left-leaning outlets like NPR and AP News covered the outcome but consistently led with language framing this as the Court "protecting" or "preserving" abortion pill access as a matter of principle. A procedural dismissal is not an endorsement.

Why Standing Matters Here

For a plaintiff to sue in federal court, they must show they've suffered a concrete, specific injury. The anti-abortion doctors argued that being forced to treat patients who experienced complications from mifepristone constituted their injury.

The Court didn't buy it — unanimously. They couldn't demonstrate a direct, traceable harm caused by the FDA's specific rule changes.

This is a significant ruling on standing doctrine. But it leaves the door open for future challengers who CAN demonstrate concrete injury. A state government. A specific hospital system. An insurer. Someone with better legal standing could take another run at these rules.

That context is largely absent from the mainstream coverage.

What Could Come Next

The FDA rules at the center of this case — specifically the changes that allowed mifepristone to be prescribed via telehealth and mailed directly to patients — remain active federal policy. But they're not legally bulletproof.

A future plaintiff with demonstrable, specific injury clears the standing hurdle. Then the case goes to the merits. And those merits involve questions about whether the FDA followed proper procedure when it expanded access in 2016 and again in 2021.

Mainstream coverage has largely ignored this possibility.

The Political Reality

The current FDA operates under the Trump administration's Health and Human Services apparatus. The administration has sent mixed signals on mifepristone. Trump himself said during the 2024 campaign that he'd leave abortion policy to states — but his FDA appointees have not moved to roll back mifepristone access either.

If the administration wanted to revisit those 2016 and 2021 rule changes through the regulatory process — not the courts — it could potentially do so without needing any plaintiff at all. That's a policy lever available to them.

The administration has not been pressed publicly on whether it will pursue this option.

What Mainstream Coverage Got Wrong

AP News called it a ruling that "keeps abortion pill available." Technically accurate. But framing a standing dismissal as active preservation misleads readers about the stability of the legal landscape.

NPR's page for their ruling coverage was unavailable — which suggests how quickly these stories get traffic and then abandoned.

The right-leaning coverage has its own problem: treating this as a total defeat when the underlying regulatory questions remain open.

The Real Story

Mifepristone is still legal, still available, and the challenge to it failed — for now, on procedural grounds. Those celebrating a permanent legal victory are getting ahead of themselves. Those declaring total defeat are missing the procedural nuance.

The Supreme Court essentially sidestepped the core questions. A unanimous sidestep, yes. But a sidestep.

The next credible challenge, from a plaintiff who can actually demonstrate injury, puts this right back in front of the federal courts. That challenge, if it comes, will have to be decided on the merits.

Pay attention to who files next.